- Conditions
- Spinal Muscular Atrophy 1
- Interventions
- AVXS-101
- Biological
- Lead sponsor
- Novartis Gene Therapies
- Industry
- Eligibility
- Up to 6 Months
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced May 22, 2026, 5:24 AM EDT